CELESTIA: Cost-Effectiveness Analysis of Empagliflozin Versus Sitagliptin in Patients with Type 2 Diabetes in Greece

PURPOSE: Globally, the prevalence of diabetes is on the rise, with the number of affected individuals predicted to cross 700 million by 2045. In Greece, in 2015, almost 700,000 people received prescribed medication for type 2 diabetes. The CELESTIA study aims to assess the cost-effectiveness of empa...

Descripción completa

Detalles Bibliográficos
Autores principales: Ghetti, Gianni, Pradelli, Lorenzo, Papageorgiou, Giannis, Karpouzos, George, Arikan, Yelda
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9942503/
https://www.ncbi.nlm.nih.gov/pubmed/36825076
http://dx.doi.org/10.2147/CEOR.S400522

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9942503/
https://www.ncbi.nlm.nih.gov/pubmed/36825076
http://dx.doi.org/10.2147/CEOR.S400522

Ejemplares similares